Flow cytometric analysis of T-cell responses to WT1 (126), WT1 (187), and proteinase 3 in AML patients
Patient . | No peptide . | WT1 (126) . | WT1 (187) . | PR3 (169) . |
---|---|---|---|---|
1 | 0.04 | 0.27*,† | 0.27*,† | 0.08 |
2 | 0.04 | 0.10* | 0.05 | 0.06 |
3 | 0.06 | 0.08 | 0.21* | 0.09 |
4 | 0.18 | 0.16 | 0.23 | 0.60* |
5 | 0.18 | 0.11† | 0.11† | 0.18 |
6 | NA | — | — | — |
7 | 0.36 | 0.40† | 0.40† | 0.38 |
8 | 0.02 | 0.04 | 0.04 | 0.05 |
9 | 0.02 | 0.03 | 0.03 | 0.02 |
10‡ | 0.64 | ND | ND | 1.34* |
0.13 | ND | ND | 0.28* | |
0.03 | ND | ND | 0.45* | |
0.31 | 0.21 | 0.32 | 0.69* | |
11 | 0.28 | 0.26† | 0.26† | 0.41 |
12 | 0.07 | 0.12† | 0.12† | 0.21* |
13 | 0.04 | 0.07 | 0.07 | 0.14* |
14 | NA | — | — | — |
15 | NA | — | — | — |
Patient . | No peptide . | WT1 (126) . | WT1 (187) . | PR3 (169) . |
---|---|---|---|---|
1 | 0.04 | 0.27*,† | 0.27*,† | 0.08 |
2 | 0.04 | 0.10* | 0.05 | 0.06 |
3 | 0.06 | 0.08 | 0.21* | 0.09 |
4 | 0.18 | 0.16 | 0.23 | 0.60* |
5 | 0.18 | 0.11† | 0.11† | 0.18 |
6 | NA | — | — | — |
7 | 0.36 | 0.40† | 0.40† | 0.38 |
8 | 0.02 | 0.04 | 0.04 | 0.05 |
9 | 0.02 | 0.03 | 0.03 | 0.02 |
10‡ | 0.64 | ND | ND | 1.34* |
0.13 | ND | ND | 0.28* | |
0.03 | ND | ND | 0.45* | |
0.31 | 0.21 | 0.32 | 0.69* | |
11 | 0.28 | 0.26† | 0.26† | 0.41 |
12 | 0.07 | 0.12† | 0.12† | 0.21* |
13 | 0.04 | 0.07 | 0.07 | 0.14* |
14 | NA | — | — | — |
15 | NA | — | — | — |
Percentage of CD3/CD8/IFN-γ–secreting T cells in response to no peptide, WT1 peptides, or proteinase 3 peptide, respectively.
Frequencies correspond to positive T-cell responses (2-fold or higher compared with PBMCs not exposed to peptide, with a minimum of 0.05% IFN-γ–producing CD3 CD8 T cells).
T-cell response was analyzed against both WT1 peptides in one sample.
Analysis of different time points in patient 10.